Limits...
Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer.

Lin A, Zhu CC, Chen HX, Chen BF, Zhang X, Zhang JG, Wang Q, Zhou WJ, Hu W, Yang HH, Xu HH, Yan WH - J. Cell. Mol. Med. (2010)

Bottom Line: HLA-G has been documented both in establishment of anti-tumour immune responses and in tumour evasion.Patient plasma sHLA-G level (≥median, 32.0 U/ml) had a significantly shorter survival time (P= 0.044); however, no similar significance was observed for the lesion HLA-G expression.In vitro data showed that both cell surface HLA-G and patient plasma sHLA-G could dramatically decrease the NK cell cytolysis.

View Article: PubMed Central - PubMed

Affiliation: Human Tissue Bank, Taizhou Hospital of Zhejiang Province, Wenzhou Medical College, Linhai, Zhejiang, China.

Show MeSH

Related in: MedlinePlus

(A) Immunohistochemical staining of HLA-G expression in primary NSCLC lesions. (a, b) lung squamous cancer with HLA-G expression. (c, d) Lung adenocarcinoma with HLA-G expression. (e) HLA-G– adenocarcinoma. (f) HLA-G– squamous cancer (original magnification: 100×). Cytotrophoblast tissues were used as internal controls (g, with mAb 4H84) and (h, with an IgG1 matched isoytpe antibody), respectively. HLA-G mAb 4H84 (1:500) was used to detect the HLA-G expression. Arrows indicate the specific staining of HLA-G expression. (B) Western blot analysis of HLA-G expression. The analysis was performed with the HLA-G mAb 4H84 (1:1000). M, molecular weight ladder; samples of patient (P1, 3, 5) were from HLA-G–, and patient (P2, 4, 6) was from HLA-G+ NSCLC patients. The degree of HLA-G expression was shown in brackets according to the case-matched immunohistochemistry data. JEG-3 and JAR lysates were used as HLA-G+ and HLA-G– controls, respectively. Isotype, a mouse IgG1 isotype antibody (1:1000) was used as internal control for JEG-3 lysates. The house keeping protein Calnexin was also used as an internal control (molecular weight: 90 kD).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3822572&req=5

fig01: (A) Immunohistochemical staining of HLA-G expression in primary NSCLC lesions. (a, b) lung squamous cancer with HLA-G expression. (c, d) Lung adenocarcinoma with HLA-G expression. (e) HLA-G– adenocarcinoma. (f) HLA-G– squamous cancer (original magnification: 100×). Cytotrophoblast tissues were used as internal controls (g, with mAb 4H84) and (h, with an IgG1 matched isoytpe antibody), respectively. HLA-G mAb 4H84 (1:500) was used to detect the HLA-G expression. Arrows indicate the specific staining of HLA-G expression. (B) Western blot analysis of HLA-G expression. The analysis was performed with the HLA-G mAb 4H84 (1:1000). M, molecular weight ladder; samples of patient (P1, 3, 5) were from HLA-G–, and patient (P2, 4, 6) was from HLA-G+ NSCLC patients. The degree of HLA-G expression was shown in brackets according to the case-matched immunohistochemistry data. JEG-3 and JAR lysates were used as HLA-G+ and HLA-G– controls, respectively. Isotype, a mouse IgG1 isotype antibody (1:1000) was used as internal control for JEG-3 lysates. The house keeping protein Calnexin was also used as an internal control (molecular weight: 90 kD).

Mentions: Overall, 41.6% (42/101) tumour lesions were classified as HLA-G+ (Table 1). In the malignant tumour sections, the intensity of staining varied from tumour to tumour and from one area to another within the same tumour. Heterogeneous staining was noted in all histological types of NSCLC. Some tumours showed focal patchy positive staining, and others displayed uniform staining pattern in tumour nests. Positive staining was observed in both the cell membrane and the sub-membranous cytoplasm region. The cytotrophoblasts were used as internal positive control for HLA-G expression. No staining was detected in corresponding adjacent normal lung tissue and tissue sections incubated with irrelevant mouse IgG1 (Fig. 1A).


Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer.

Lin A, Zhu CC, Chen HX, Chen BF, Zhang X, Zhang JG, Wang Q, Zhou WJ, Hu W, Yang HH, Xu HH, Yan WH - J. Cell. Mol. Med. (2010)

(A) Immunohistochemical staining of HLA-G expression in primary NSCLC lesions. (a, b) lung squamous cancer with HLA-G expression. (c, d) Lung adenocarcinoma with HLA-G expression. (e) HLA-G– adenocarcinoma. (f) HLA-G– squamous cancer (original magnification: 100×). Cytotrophoblast tissues were used as internal controls (g, with mAb 4H84) and (h, with an IgG1 matched isoytpe antibody), respectively. HLA-G mAb 4H84 (1:500) was used to detect the HLA-G expression. Arrows indicate the specific staining of HLA-G expression. (B) Western blot analysis of HLA-G expression. The analysis was performed with the HLA-G mAb 4H84 (1:1000). M, molecular weight ladder; samples of patient (P1, 3, 5) were from HLA-G–, and patient (P2, 4, 6) was from HLA-G+ NSCLC patients. The degree of HLA-G expression was shown in brackets according to the case-matched immunohistochemistry data. JEG-3 and JAR lysates were used as HLA-G+ and HLA-G– controls, respectively. Isotype, a mouse IgG1 isotype antibody (1:1000) was used as internal control for JEG-3 lysates. The house keeping protein Calnexin was also used as an internal control (molecular weight: 90 kD).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3822572&req=5

fig01: (A) Immunohistochemical staining of HLA-G expression in primary NSCLC lesions. (a, b) lung squamous cancer with HLA-G expression. (c, d) Lung adenocarcinoma with HLA-G expression. (e) HLA-G– adenocarcinoma. (f) HLA-G– squamous cancer (original magnification: 100×). Cytotrophoblast tissues were used as internal controls (g, with mAb 4H84) and (h, with an IgG1 matched isoytpe antibody), respectively. HLA-G mAb 4H84 (1:500) was used to detect the HLA-G expression. Arrows indicate the specific staining of HLA-G expression. (B) Western blot analysis of HLA-G expression. The analysis was performed with the HLA-G mAb 4H84 (1:1000). M, molecular weight ladder; samples of patient (P1, 3, 5) were from HLA-G–, and patient (P2, 4, 6) was from HLA-G+ NSCLC patients. The degree of HLA-G expression was shown in brackets according to the case-matched immunohistochemistry data. JEG-3 and JAR lysates were used as HLA-G+ and HLA-G– controls, respectively. Isotype, a mouse IgG1 isotype antibody (1:1000) was used as internal control for JEG-3 lysates. The house keeping protein Calnexin was also used as an internal control (molecular weight: 90 kD).
Mentions: Overall, 41.6% (42/101) tumour lesions were classified as HLA-G+ (Table 1). In the malignant tumour sections, the intensity of staining varied from tumour to tumour and from one area to another within the same tumour. Heterogeneous staining was noted in all histological types of NSCLC. Some tumours showed focal patchy positive staining, and others displayed uniform staining pattern in tumour nests. Positive staining was observed in both the cell membrane and the sub-membranous cytoplasm region. The cytotrophoblasts were used as internal positive control for HLA-G expression. No staining was detected in corresponding adjacent normal lung tissue and tissue sections incubated with irrelevant mouse IgG1 (Fig. 1A).

Bottom Line: HLA-G has been documented both in establishment of anti-tumour immune responses and in tumour evasion.Patient plasma sHLA-G level (≥median, 32.0 U/ml) had a significantly shorter survival time (P= 0.044); however, no similar significance was observed for the lesion HLA-G expression.In vitro data showed that both cell surface HLA-G and patient plasma sHLA-G could dramatically decrease the NK cell cytolysis.

View Article: PubMed Central - PubMed

Affiliation: Human Tissue Bank, Taizhou Hospital of Zhejiang Province, Wenzhou Medical College, Linhai, Zhejiang, China.

Show MeSH
Related in: MedlinePlus